Research and Markets (http://www.researchandmarkets.com/research/wh2456/brexpiprazole)
has announced the addition of the "Brexpiprazole
(Major Depressive Disorder) - Forecast and Market Analysis to 2023"
report to their offering.
Otsuka Pharmaceutical initially developed Brexpiprazole but in 2011, the
pharmaceutical company entered an agreement with Lundbeck for the
co-development and co-commercialization of this product. The product is
in Phase III development as an adjunctive therapy for MDD in the US and
Europe, and is also being developed for the treatment of schizophrenia,
anxiety disorders, dementia, post-traumatic stress disorder (PTSD),
sleep disorders, and ADHD.
Overview of Major depressive disorder, including epidemiology,
etiology, symptoms, diagnosis, pathology and treatment guidelines as
well as an overview on the competitive landscape.
Detailed information on Brexpiprazole including product description,
safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Brexpiprazole for the top eight countries from 2013
Sales information covered for the US, France, Germany, Italy, Spain,
the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
Symptoms and Subtypes of Major Depressive Disorder
Quality of Life
4 Disease Management
Treatment Guidelines and Leading Prescribed Drugs
5 Competitive Assessment
6 Unmet Needs and Opportunities
More Effective Pharmacotherapies
More Favorable Side Effect Profiles
Rapid Onset of Antidepressant Effects
Personalized Treatment Approach
7 Pipeline Assessment
8 Brexpiprazole (OPC-34712)
Dosing and Formulation
Potential Clinical and Commercial Positioning
For more information visit http://www.researchandmarkets.com/research/wh2456/brexpiprazole
Copyright Business Wire 2014